Table 2.

Characteristics of the 16 patients who received neratinib (N, %)^a

Age, years
Median (range)	58 (31–74)
Race
White/African American/Asian	13 (81%)/1 (6%)/2 (13%)
ECOG PS
0/1/2	9 (56%)/7 (44%)/0 (0%)
Menopausal status
Pre-/postmenopausal	2 (12%)/14(88%)
Histology
Ductal/lobular	11 (67%)/5 (31.3%)
Hormone receptor status
ER+PR+/ER+PR−/ER−PR−HER2−	7 (44%)/8 (50%)/1 (6%)
HER2 status
Nonamplified/amplified	16 (100%)/0 (0%)
Evaluable disease by RECIST
Measurable/nonmeasurable	13 (81%)/3 (19%)
Disease magnitude
Visceral/nonvisceral	11 (69%)/5 (31%)
Prior number of metastatic regimens
Any/endocrine/chemo (median, range)	3 (2–10)/2 (0–3)/2 (0–6)
Reason off study
Adverse event/progressive disease	1 (6%)/15 (94%)

^aUnless otherwise specified.